This article provides a licensable picture of Phillips 66 CEO Mark Lashier speaking at the Reuters Global Energy Forum in New York City on June 24, 2026. The image, taken by Julian Guideras/Handout via REUTERS, is available through Reuters Connect. The provided metadata includes image dimensions, credit, source, and byline.

Royal Caribbean has expanded Ben Bouldin's role from president of Greater China to include managing director of Asia, encompassing the broader Asia region. This move aims to strengthen regional alignment and support long-term growth in Asia, a key strategic market for the cruise line. Bouldin brings over a decade of international leadership experience with Royal Caribbean, having previously led operations across the UK, Europe, the Middle East, Africa, and most recently, China.

MSCI Inc. has acquired First Street, a specialist in physics-based climate risk data, for $120 million, with potential for additional payments. This acquisition aims to enhance MSCI's global physical climate risk capabilities, integrating First Street's models to provide detailed assessments of climate risk for properties worldwide. The deal strengthens MSCI's market position in climate investment tools, helping institutions meet regulatory requirements and improve financial decision-making related to climate hazards.

B.Riley has initiated coverage on Suncrete Inc (NASDAQ: RMIX) with a Buy rating and a $26.00 price target, highlighting the company's unique position as the only pure-play ready-mix concrete stock in US public markets. The firm points to Suncrete's successful "roll-up playbook," which has led to significant expansion through acquisitions, and projects strong revenue and EBITDA growth. InvestingPro data suggests the stock is currently slightly overvalued, but analysts anticipate profitability this year.

This article compares Arista Networks (ANET) and Cisco Systems (CSCO) as investments in the AI data center market. Arista is presented as a pure-play AI networking company with higher revenue growth, operating margins, and potential annualized returns, while Cisco is a more diversified, established giant with accelerating AI orders but slower overall growth due to legacy businesses. TIKR's valuation models suggest significantly higher annualized returns for Arista compared to Cisco.

SLB (Schlumberger) stock has experienced a -15% slide over a 6-day losing streak, resulting in a market cap decrease of approximately $13 billion. Despite this, the article suggests that SLB's "Weak operating performance and financial condition" are not fully reflected in its "Moderate valuation," deeming it "Unattractive." The piece also highlights the importance of predictive signals over notifications for managing stock-specific risk and provides a comparison of SLB's returns against the S&P 500.

CSX (CSX) has experienced mixed short-term stock performance but has shown strong returns over the past 3 months and year. Despite recent infrastructure improvements expected to boost efficiency and revenue, the stock appears fully priced according to an intrinsic value estimate and is trading above its estimated fair P/E ratio, suggesting limited upside without further growth or execution. Investors should consider the potential for execution risks and market sensitivity to industrial demand.

BlackRock has formally recommended that investors allocate 1% to 2% of their portfolios to Bitcoin, marking a significant step in the cryptocurrency's institutional acceptance. This guidance, provided through a BlackRock Investment Institute research note, positions Bitcoin as a complementary diversifier that can enhance portfolio diversification and risk-adjusted returns. The move is expected to accelerate adoption among financial advisors and wealth managers, providing a formal framework for discussing crypto allocations with clients.

Paychex Inc. has reported its earnings for the quarter that ended on May 31. The summary of these results is provided in a brief statement, as per Refinitiv.

Mizuho analyst Salim Syed has increased Amgen Inc.'s (AMGN) price target to $303 from $295, maintaining a Neutral rating, following a review of the company's first-quarter results. Amgen also presented new data at the ADA 86th Scientific Sessions, showing its drug Repatha significantly reduced major cardiovascular events in high-risk diabetes patients. The company is gaining attention in the weight-loss market with its experimental drug MariTide, currently in Phase 3 trials.